Endpoints News reports on Micron’s fundraise and the positive start to 2025. Below are a few excepts:
…Micron Biomedical has started 2025 on a positive note, raising over $16 million in a Series A extension round. The funding will be used to manufacture its vaccine “button” technology as it gears up for a potential commercial launch in 2027, CEO Steve Damon told Endpoints News. …
…The Series A extension was led by J2 Ventures and the Global Health Investment Corporation and brings the total raise to $33 million. J2 Venture’s general partner Matt Goldman will join Micron’s board of directors. …
…Once Micron’s vaccine button is pressed, the vaccine dissolves into the skin then the device is peeled off, Damon said. This is different from other patch technology….
…Damon said the tech could be used for vaccines that are stockpile targets, as the patches are easier to store for longer periods compared to needle injections. This is due to the “dry” nature of the patch not requiring cold supply chains. The tech is also being investigated for medicines
To read the full article click the link below (subscription required)